Drug Profile
Research programme: mimotope B cell vaccines - Imugene/Medical University of Vienna
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Imugene; Medical University of Vienna
- Class Cancer vaccines; Peptide vaccines; Peptides; Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cancer in Australia (unspecified route)
- 31 Aug 2023 Discontinued - Preclinical for Cancer in Austria (unspecified route)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Australia